Related Experiment Videos
Mitral valve replacement after percutaneous transluminal mitral commissurotomy
Makoto Kamada1, Kenji Ohsaka, Susumu Nagamine
1Department of Cardiovascular Surgery, Iwate Prefectural Central Hospital, Morioka, Iwate, Japan.
The Japanese Journal of Thoracic and Cardiovascular Surgery : Official Publication of the Japanese Association for Thoracic Surgery = Nihon Kyobu Geka Gakkai Zasshi
|August 7, 2004
Summary
Mitral valve replacement (MVR) after percutaneous transluminal mitral commissurotomy (PTMC) for mitral stenosis (MS) showed reasonable outcomes despite high risks. Close follow-up is crucial for managing restenosis and complications.
Area of Science:
- Cardiology
- Cardiac Surgery
- Interventional Cardiology
Background:
- Rheumatic mitral stenosis (MS) is a significant valvular heart disease.
- Percutaneous transluminal mitral commissurotomy (PTMC) is a less invasive treatment option for MS.
- Some patients require subsequent mitral valve replacement (MVR) due to restenosis or regurgitation.
Purpose of the Study:
- To review the experience and outcomes of mitral valve replacement (MVR) in patients who previously underwent percutaneous transluminal mitral commissurotomy (PTMC) for mitral stenosis (MS).
- To evaluate the effectiveness and complications associated with MVR following PTMC.
Main Methods:
- A retrospective review of 75 patients who underwent PTMC for symptomatic rheumatic MS between December 1987 and December 2001.
- Analysis of patients who subsequently required MVR, noting the interval between procedures, reasons for MVR (restenosis or regurgitation), and clinical outcomes.
- Assessment of changes in mitral valve area (MVA), left atrial dimension (LAD), and tricuspid regurgitation (TR) before and after interventions.
Main Results:
- 11 patients (14.7%) underwent MVR at a mean follow-up of 8.4 years after PTMC, primarily for mitral restenosis (9 cases).
- MVR carried a significant risk, with 2 hospital deaths and 2 major complications (prosthetic valve endocarditis, left ventricular rupture).
- While PTMC improved mitral valve area (MVA) and New York Heart Association (NYHA) class initially, MVA decreased and NYHA class deteriorated by the time of MVR. Tricuspid regurgitation (TR) also increased.
Conclusions:
- MVR after PTMC is a feasible option but associated with considerable risks.
- For patients with congestive heart failure and significant TR, MVR combined with tricuspid annuloplasty may be a preferable initial intervention over PTMC.
- Regular echocardiographic follow-up is essential to monitor for mitral restenosis, TR progression, and cardiac chamber dilatation.